This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) consists of insights across gene therapies for rare genetic disorders of retina, central nervous system, mitochondrial diseases, hearing disorders, and renal diseases. Therapeutic biomarker for organ anti-aging, next generation cell and gene therapies, drug delivery technologies, therapeutics for neurological diseases, and COVID-19 vaccines are also discussed. Further, weight management, novel liquid oxygen sensing technology, and new class of antibiotics are also described. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Adeno-associated viral gene therapy, rare genetic disorders, retinal disorders, mitochondrial genetic diseases, renal (kidney) diseases, organ anti-aging, organ regeneration, congenital and acquired hearing loss, site specific gene editing, gene repair, next generation cell and gene therapies, chip-based drug delivery technology, gene delivery system, RNAi therapeutics, asthma, breast cancer, mammography, oximeters, oxygen monitoring, drug delivery, cystic fibrosis, weight management, neurological disorders, COVID-19 vaccines, hereditary angioedema